CKD Bio Corp.
063160.KS
Get informed when a big investor buys or sells
+ FollowMarket Cap$76.86B
Close$
Share Statistics
| Market cap | $76.86 Billion |
|---|---|
| Enterprise Value | $224.47 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-526.16 |
| Beta | 0.33 |
| Outstanding Shares | 5,486,000 |
Return
| Return on Equity | -8.98% |
|---|---|
| Return on Assets | -3.67% |
| Return on Invested Capital | -4.38% |
Valuation & Multiples
| P/E Ratio | -7.16 |
|---|---|
| PEG | -0.7 |
| Price to Sales | 0.46 |
| Price to Book Ratio | 0.61 |
| Enterprise Value to Revenue | 1.42 |
| Enterprise Value to EBIT | -30.5 |
| Enterprise Value to Net Income | -21 |
| Total Debt to Enterprise | 0.66 |
| Debt to Equity | 1.24 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 31, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$44.80 B
Average shareholder expectationNext Earnings Call
Expected Date
November 18, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$44.80 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About CKD Bio Corp.
533 employees
CEO: Wan-Kap Park CKD Bio Corp., a South Korean company founded in 1941 and headquartered in Seoul, specializes in the production and distribution of pharmaceutical active ingredients (APIs). Their manufacturing processes leverage diverse technologies, in...